- Home
- PEGA vs LNTH Comparison
PEGA vs LNTH Comparison
Compare PEGA & LNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PEGA
- LNTH
- Stock Information
- Founded
- PEGA 1983
- LNTH 1956
- Country
- PEGA United States
- LNTH United States
- Employees
- PEGA N/A
- LNTH N/A
- Industry
- PEGA EDP Services
- LNTH Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- PEGA Technology
- LNTH Health Care
- Exchange
- PEGA Nasdaq
- LNTH Nasdaq
- Market Cap
- PEGA 9.4B
- LNTH 5.7B
- IPO Year
- PEGA 1996
- LNTH 2015
- Fundamental
- Price
- PEGA $50.11
- LNTH $81.47
- Analyst Decision
- PEGA Buy
- LNTH Strong Buy
- Analyst Count
- PEGA 14
- LNTH 5
- Target Price
- PEGA $51.07
- LNTH $131.20
- AVG Volume (30 Days)
- PEGA 1.7M
- LNTH 952.8K
- Earning Date
- PEGA 07-22-2025
- LNTH 07-30-2025
- Dividend Yield
- PEGA 0.12%
- LNTH N/A
- EPS Growth
- PEGA 156.48
- LNTH N/A
- EPS
- PEGA 1.07
- LNTH 3.53
- Revenue
- PEGA $1,642,666,000.00
- LNTH $1,536,699,000.00
- Revenue This Year
- PEGA $14.21
- LNTH $4.63
- Revenue Next Year
- PEGA $6.55
- LNTH $9.35
- P/E Ratio
- PEGA $46.58
- LNTH $23.03
- Revenue Growth
- PEGA 14.29
- LNTH 12.53
- 52 Week Low
- PEGA $29.00
- LNTH $73.11
- 52 Week High
- PEGA $56.84
- LNTH $126.89
- Technical
- Relative Strength Index (RSI)
- PEGA 47.42
- LNTH 50.75
- Support Level
- PEGA $51.79
- LNTH $78.74
- Resistance Level
- PEGA $55.28
- LNTH $85.31
- Average True Range (ATR)
- PEGA 1.69
- LNTH 2.28
- MACD
- PEGA -0.28
- LNTH 0.51
- Stochastic Oscillator
- PEGA 35.03
- LNTH 45.38
About PEGA Pegasystems Inc.
Founded in 1983, Pegasystems provides a suite of solutions for customer engagement and business process management. The company's key offering is the Pega Infinity platform, which combines business process management with customer relationship management applications. The company focuses on enterprise-size customers in the financial, insurance, and healthcare industries.
About LNTH Lantheus Holdings Inc.
Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes license of RELISTOR to Bausch Health Companies, Inc.